Healthcare - Biotechnology - NYSE - CH
$ 2.39
-9.81 %
$ 231 M
Market Cap
-1.0
P/E
INCOME STATEMENT
69.6 M
REVENUE
-166 M
OPERATING INCOME
-240 M
NET INCOME
EFFICIENCY
Earnings Waterfall
ADC Therapeutics SA
| Revenue | 69.6 M |
| Cost Of Revenue | 2.53 M |
| Gross Profit | 67 M |
| Operating Expenses | 233 M |
| Operating Income | -166 M |
| Other Expenses | 74.1 M |
| Net Income | -240 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Revenue | 69.6 | 209.9 | 33.9 | 0 | 2.3 | 1.1 | 1.8 |
| GROSS PROFIT | |||||||
| Cost Of Revenue | 2.5 | 4.6 | 1.4 | 2.0 | 107.5 | 118.1 | 85.5 |
| Gross Profit | 67.0 | 205.3 | 32.5 | (2.0) | (105.2) | (116.9) | (83.7) |
| OPERATING INCOME | |||||||
| Operating Expenses | 233.0 | 329.0 | 294.2 | 219.3 | 121.7 | 127.1 | 93.5 |
| Selling, General and Administrative Expenses | 105.9 | 141.1 | 136.2 | 77.2 | 13.8 | 8.6 | 7.8 |
| Research and Development Expenses | 127.1 | 187.9 | 158.0 | 142.0 | 107.5 | 118.3 | 85.5 |
| Operating Income | (166.0) | (123.6) | (261.7) | (219.3) | (119.4) | (125.9) | (91.7) |
| PRE-TAX INCOME | |||||||
| Interest Income Expense | 46.3 | 36.9 | 18.3 | 4.9 | 0.2 | 0 | 0 |
| Total Other Income | (29.4) | (33.6) | 10.2 | (26.7) | 3.5 | 3.1 | 1.9 |
| Pre-Tax Income | (195.4) | (154.7) | (251.5) | (246.0) | (115.9) | (122.9) | (89.8) |
| NET INCOME | |||||||
| Tax Provision | 39.1 | 1.1 | (21.5) | 0.3 | 0.6 | 0.2 | 48 K |
| Net Income | (240.1) | (155.8) | (230.0) | (246.3) | (116.5) | (123.1) | (89.9) |
| EPS | 2.94 | 1.99 | 3 | 3.77 | 1.74 | 2.29 | 1.53 |